Fischer Medical Ventures Ltd (FISCHER) — shareholding pattern, promoter holding, financials and share price
About Fischer Medical Ventures Ltd (FISCHER)
Fischer Medical Ventures Ltd operates in the Medical Equipment & Supplies industry, within the Healthcare sector. It trades on the NSE as FISCHER and on the BSE under scrip code 524743. Its ISIN is INE771F01041.
Incorporated in 1993, Fischer Chemic Ltd does trading of chemicals and machineries [1]
Fischer Medical Ventures Limited specializes in developing advanced, affordable MRI systems, located in the Andhra Pradesh MedTech Zone. It has a significant international footprint and is focused on enhancing medical imaging accessibility worldwide.
The company saw a remarkable growth in revenue, increasing by 118% year-on-year to INR 86 crores for Q2 FY26, and maintains a strong EBITDA margin of 21%.
Listed peers in Medical Equipment & Supplies: Tarsons Products Ltd, Q-Line Biotech Ltd, Laxmi Dental Ltd, OSEL Devices Ltd, Fabtech Technologies Ltd, Vasa Denticity Ltd.
Valuation & Returns
10 Jul 2026At ₹38.49 a share on 10 Jul 2026, Fischer Medical Ventures Ltd (FISCHER) was valued at a price-to-earnings ratio of 81.19x against an industry P/E of 44.11x and a price-to-book of 7.46x on a book value of ₹5.16 per share as of Mar 2025. Solomo computes return on equity of 9.19% and return on capital employed of 12.35% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 81.19x
- Industry P/E
- 44.11x
- P/B
- 7.46x
- EPS (TTM)
- ₹0.47
- Book value / share
- ₹5.16
- ROE
- 9.19%
- ROCE
- 12.35%
- ROA
- 6.78%
- Debt / equity
- 0.25x
- Dividend yield
- 0.01%
- EBITDA margin
- 17.9%
- 52-week range
- ₹31.13 – ₹124.2
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Fischer Medical Ventures Ltd (FISCHER) reported revenue of ₹309 crore, net profit of ₹31 crore and earnings per share of ₹0.47. That compares with revenue of ₹111 crore and net profit of ₹1 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹97.73 crore and net profit ₹-7.1 crore (consolidated).
| Metric | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Revenue (₹ cr) | 0 | 21 | 111 | 309 |
| Net profit (₹ cr) | 0 | 2 | 1 | 31 |
| EPS (₹) | -0.24 | 0.03 | 0.02 | 0.47 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | - | 95.26% | - | 427.65% |
| Profit growth | - | - | - | -34.24% |
| Stock price CAGR | 71% | 61% | 49% | -59% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 62.15% of Fischer Medical Ventures Ltd (FISCHER) (unchanged from the previous quarter), foreign institutional investors (FII) hold 5.48% and domestic institutional investors (DII) hold 1.35%. Promoters have pledged 7.4% of their holding. Market capitalisation was ₹2,519 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2001.
Largest disclosed public shareholders in Jun 2026: ROOPAL HITESH KAWA . 2.71%, VIKASA INDIA EIF I FUND 2.54%, INDIA EMERGING GIANTS FUND LIMITED 2.48%, HUF 1.95%, VINAY RAJENDRAKUMAR NAGDA 1.53%, BLUE LOTUS CAPITAL MULTI BAGGER FUND II 1.35%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 62.15% | 7.4% | 5.48% | 1.35% | 37.85% |
| Mar 2026 | 62.15% | 7.4% | 4.97% | 1.38% | 37.85% |
| Dec 2025 | 61.8% | - | 4.85% | 1.36% | 38.2% |
| Sep 2025 | 61.8% | - | 5.57% | 1.42% | 38.2% |
| Jun 2025 | 61.8% | - | 5.55% | 1.42% | 38.2% |
| Mar 2025 | 62.81% | - | 5.23% | 1.44% | 37.19% |
| Dec 2024 | 74.91% | - | 5.07% | 1.68% | 25.09% |
| Sep 2024 | 74.91% | - | 5.07% | 1.68% | 25.09% |